Published:
Northwest Biotherapeutics to Present at Next Generation Vaccine Conference
BETHESDA, Md., July 18 /PRNewswire-FirstCall/ -- Northwest
Biotherapeutics, Inc. (AIM: NWBS and NWBT; OTC Bulletin Board: NWBO), (the
"Company or NWBT"), today announced that Dr. Alton L. Boynton, its President
and Chief Executive Officer, will deliver a presentation updating the
Company's progress in the development of dendritic vaccines for the treatment
of cancer, at the "Next Generation Vaccines" conference. The conference will
be held on 17 &18 July, at the Gaylord National Resort and Convention Center
in National Harbor,Maryland, USA. Dr. Boynton is scheduled to present as part
of the Advances in Cancer Vaccines session on July 18th @ 11:15 am EST.
Dr. Boynton will provide an update on NWBT's product candidates, including
therapeutic cancer vaccines DCVax(R)-Brain for the treatment of Glioblastoma
multiforme and DCVax(R)-Prostate for hormone-independent prostate cancer.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing
immunotherapy products that treat cancers more effectively than current
treatments, without toxicity, on a cost-effective basis. The Company has two
broad platform technologies: dendritic cell-based vaccines and therapeutic
antibodies. The Company is currently conducting a large Phase II clinical
trial in GBM, which is designed and powered to serve as a pivotal trial. The
Company has also received clearance from the FDA for a large Phase III trial
in prostate cancer, and clearance from the FDA for Phase I trials in five
other cancers. The Company has started a Phase I/II trial with DCVax(R)
directed to ovarian cancer. The Company's second technology platform,
involving antibodies to CXCR4, is at the late pre-clinical development stage.
For further information, please visit the company web site at
http://www.nwbio.com
Statements made in this news release that are not historical facts are
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Words such as "expects," "believes,"
"intends," and similar expressions are intended to identify forward-looking
statements. Actual results may differ materially from those projected in any
forward-looking statement. Specifically, there are a number of important
factors that could cause actual results to differ materially from those
anticipated, such as the Company's ability to raise additional capital, risks
related to the Company's ability to enroll patients in the Phase II trial of
DCVax(R)-Brain and complete the trial on a timely basis, risks related to
meeting the clinical endpoints in the planned Phase II clinical trial of
DCVax(R)-Brain, risks related to manufacturing, risks related to the Company's
ability to initiate, and enroll patients in, the planned Phase III trial of
DCVax(R)-Prostate and complete the trial on a timely basis, the uncertainty of
the clinical trials process and whether DCVax(R)-Prostate or DCVax(R)-Brain
will demonstrate safety and efficacy, and the timely performance of third
parties. Additional information on these and other factors, which could
affect the Company's results, is included in its Securities and Exchange
Commission filings. Finally, there may be other factors not mentioned above
or included in the Company's SEC filings that may cause actual results to
differ materially from those projected in any forward-looking statement. You
should not place undue reliance on any forward-looking statements. The
Company assumes no obligation to update any forward-looking statements as a
result of new information, future events or developments, except as required
by securities laws.
SOURCE Northwest Biotherapeutics
Copyright © 2008, PRNewswire
Copyright © 2008, NewsBlaze,
Daily NewsTags: Healthcare, Biotechnology, Pharmaceuticals, Health, , maryl and
_ _Is your favorite bookmark site missing?
Ask for it.
Search News
Daily News
